FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316362912> ?p ?o ?g. }

• W4316362912 endingPage "661" @default.
• W4316362912 startingPage "647" @default.
• W4316362912 abstract "Gepotidacin is a novel triazaacenaphthylene antibiotic in phase III development. Based on nonclinical in vitro characterization of gepotidacin metabolism, two phase I studies were conducted in healthy participants to investigate clinical drug-drug interactions (DDIs). We assessed gepotidacin as a DDI victim with a potent cytochrome P450 (CYP) 3A4/P-glycoprotein (P-gp) inhibitor (itraconazole), potent CYP3A4 inducer (rifampicin), and nonspecific organic cation transporter (OCT)/multidrug and toxic extrusion transporter (MATE) renal transport inhibitor (cimetidine) via single doses of gepotidacin before and after co-administration with multiple doses of the modulator drugs. Gepotidacin DDI perpetrator potential for P-gp inhibition (digoxin) and CYP3A4 inhibition (midazolam) was evaluated via single doses of the two-drug cocktail without and with gepotidacin. The DDI magnitudes were interpreted based on area under the concentration-time curve (AUC). A weak DDI (AUC increase 48%-50%) was observed for gepotidacin co-administered with itraconazole. A clinically significant decrease in gepotidacin plasma AUC (52%) was observed with rifampicin coadministration, indicating a moderate DDI. There was no DDI for gepotidacin with cimetidine; a unique biomarker approach showed increased serum creatinine (24%), decreased renal clearance of creatinine (21%), and N1-methylnicotinamide (39%), which confirmed extensive MATE inhibition and partial OCT2 inhibition. Gepotidacin was not a P-gp DDI perpetrator, although the maximum plasma concentration of digoxin increased (53%) and is potentially clinically relevant given its narrow therapeutic index. Gepotidacin demonstrated weak CYP3A4 inhibition with midazolam (<2-fold AUC increase). There were no new safety-risk profile findings. These results will inform the safe and efficacious clinical use of gepotidacin when co-administered with other drugs." @default.
• W4316362912 created "2023-01-16" @default.
• W4316362912 creator A5004846236 @default.
• W4316362912 creator A5010774536 @default.
• W4316362912 creator A5023256422 @default.
• W4316362912 creator A5036874083 @default.
• W4316362912 creator A5047102805 @default.
• W4316362912 creator A5052624686 @default.
• W4316362912 creator A5070870574 @default.
• W4316362912 creator A5072952672 @default.
• W4316362912 creator A5086044754 @default.
• W4316362912 creator A5087617559 @default.
• W4316362912 date "2023-01-23" @default.
• W4316362912 modified "2023-09-27" @default.
• W4316362912 title "Clinical assessment of gepotidacin (<scp>GSK2140944</scp>) as a victim and perpetrator of <scp>drug–drug</scp> interactions via <scp>CYP3A</scp> metabolism and transporters" @default.
• W4316362912 cites W2004281677 @default.
• W4316362912 cites W2008440205 @default.
• W4316362912 cites W2033257318 @default.
• W4316362912 cites W2050358940 @default.
• W4316362912 cites W2077067141 @default.
• W4316362912 cites W2077074606 @default.
• W4316362912 cites W2079197876 @default.
• W4316362912 cites W2097913161 @default.
• W4316362912 cites W2102006967 @default.
• W4316362912 cites W2107567029 @default.
• W4316362912 cites W2123781057 @default.
• W4316362912 cites W2146778078 @default.
• W4316362912 cites W2157262647 @default.
• W4316362912 cites W2171273833 @default.
• W4316362912 cites W2180446115 @default.
• W4316362912 cites W2227782493 @default.
• W4316362912 cites W2554935731 @default.
• W4316362912 cites W2570305595 @default.
• W4316362912 cites W2591541276 @default.
• W4316362912 cites W2777266505 @default.
• W4316362912 cites W2803333994 @default.
• W4316362912 cites W2892317473 @default.
• W4316362912 cites W2896835015 @default.
• W4316362912 cites W2914873171 @default.
• W4316362912 cites W2952741202 @default.
• W4316362912 cites W3015764830 @default.
• W4316362912 cites W3026222235 @default.
• W4316362912 cites W3122506535 @default.
• W4316362912 cites W3205374264 @default.
• W4316362912 cites W4220757928 @default.
• W4316362912 cites W4226301568 @default.
• W4316362912 cites W4283735763 @default.
• W4316362912 cites W4316362912 @default.
• W4316362912 doi "https://doi.org/10.1111/cts.13477" @default.
• W4316362912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36642822" @default.
• W4316362912 hasPublicationYear "2023" @default.
• W4316362912 type Work @default.
• W4316362912 citedByCount "1" @default.
• W4316362912 countsByYear W43163629122023 @default.
• W4316362912 crossrefType "journal-article" @default.
• W4316362912 hasAuthorship W4316362912A5004846236 @default.
• W4316362912 hasAuthorship W4316362912A5010774536 @default.
• W4316362912 hasAuthorship W4316362912A5023256422 @default.
• W4316362912 hasAuthorship W4316362912A5036874083 @default.
• W4316362912 hasAuthorship W4316362912A5047102805 @default.
• W4316362912 hasAuthorship W4316362912A5052624686 @default.
• W4316362912 hasAuthorship W4316362912A5070870574 @default.
• W4316362912 hasAuthorship W4316362912A5072952672 @default.
• W4316362912 hasAuthorship W4316362912A5086044754 @default.
• W4316362912 hasAuthorship W4316362912A5087617559 @default.
• W4316362912 hasBestOaLocation W43163629121 @default.
• W4316362912 hasConcept C104317684 @default.
• W4316362912 hasConcept C109650736 @default.
• W4316362912 hasConcept C112705442 @default.
• W4316362912 hasConcept C11824378 @default.
• W4316362912 hasConcept C123584848 @default.
• W4316362912 hasConcept C126322002 @default.
• W4316362912 hasConcept C133936738 @default.
• W4316362912 hasConcept C149011108 @default.
• W4316362912 hasConcept C185592680 @default.
• W4316362912 hasConcept C2777707475 @default.
• W4316362912 hasConcept C2778198053 @default.
• W4316362912 hasConcept C2778607973 @default.
• W4316362912 hasConcept C2778707650 @default.
• W4316362912 hasConcept C2780035454 @default.
• W4316362912 hasConcept C2780272996 @default.
• W4316362912 hasConcept C2780306776 @default.
• W4316362912 hasConcept C2780719153 @default.
• W4316362912 hasConcept C501593827 @default.
• W4316362912 hasConcept C526171541 @default.
• W4316362912 hasConcept C55493867 @default.
• W4316362912 hasConcept C62231903 @default.
• W4316362912 hasConcept C71924100 @default.
• W4316362912 hasConcept C76318530 @default.
• W4316362912 hasConcept C89311334 @default.
• W4316362912 hasConcept C97320921 @default.
• W4316362912 hasConcept C98274493 @default.
• W4316362912 hasConceptScore W4316362912C104317684 @default.
• W4316362912 hasConceptScore W4316362912C109650736 @default.
• W4316362912 hasConceptScore W4316362912C112705442 @default.
• W4316362912 hasConceptScore W4316362912C11824378 @default.
• W4316362912 hasConceptScore W4316362912C123584848 @default.
• W4316362912 hasConceptScore W4316362912C126322002 @default.

• next